Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2026)

Royalty Pharma has disclosed Total Current Liabilities across 8 years of filings, most recently posting $535.7 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $535.7 million, down 54.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $535.7 million (down 54.71% YoY), and the FY2025 annual result was $636.2 million, down 49.25% from the prior year.
• Total Current Liabilities came in at $535.7 million for Q1 2026 at Royalty Pharma, down from $636.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q4 2024 to a low of $124.6 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $636.2 million (2025), against an average of $712.3 million.
• Across the five-year window, Total Current Liabilities plunged 88.85% in 2024 and soared 849.52% in 2025, its largest moves.
• Royalty Pharma's Total Current Liabilities stood at $1.2 billion in 2022, then sank by 86.17% to $161.4 million in 2023, then soared by 676.82% to $1.3 billion in 2024, then tumbled by 49.25% to $636.2 million in 2025, then declined by 15.8% to $535.7 million in 2026.
• The last three Total Current Liabilities figures came in at $535.7 million (Q1 2026), $636.2 million (Q4 2025), and $530.8 million (Q3 2025), per Business Quant data.